Galera Therapeutics, LLC., a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics that have the potential to transform radiotherapy in cancer, has appointed an accomplished pharmaceutical sales, market access, and commercial operations executives to Galera’s senior commercial leadership team, effective immediately.

Under the direction of Mark Bachleda, Galera’s chief commercial officer, the team will be responsible for building out the Company’s commercial operations, strategy development, and execution in preparation for the potential U.S. commercial launch of avasopasem in 2023.

The Company’s appointments include:
• Patrick Campbell as Vice President of Sales & Account Management
• Elizabeth Turner as Vice President of Market Access
• Henning Thorsen as Vice President of Commercial Operations

The new senior leaders join Lorraine Walker, Galera’s vice president of marketing.

“We are excited to expand our commercial team with the appointments of leading biopharmaceutical executives Pat, Liz, and Henning, who bring decades of commercialization expertise in launching market-leading oncology therapies in the U.S.,” said Bachleda. “We look forward to leveraging their leadership and commercial capabilities as Galera approaches a pivotal moment in its trajectory to becoming a commercial-stage company.”

Campbell has over 30 years of commercial leadership experience launching 11 new products in the oncology marketplace. Campbell joins Galera from Amgen, Inc. where he recently served as Executive National Sales Director for Amgen’s oncology solid tumor portfolio. He led the buildout of a new U.S. oncology sales division responsible for the successful launch of Lumakras to treat KRAS G12C-mutated non-small cell lung cancer.

Turner has nearly 20 years of commercial experience in the biopharmaceutical and healthcare industries across market access, sales, and marketing. Turner joins Galera from Anton Health, a market access consulting firm, where she served as vice president. Before Anton Health, Turner served as vice president, global market access at Arena Pharmaceuticals and was responsible for creating their global market access platform in the U.S. and Europe including pricing, distribution, reimbursement, and patient services to support the planned commercial launch of etrasimod, prior to Arena’s acquisition by Pfizer for $6.7 billion.

Thorsen is an accomplished commercial executive with over 30 years in the biotech industry, the last ten years focused on small biotech commercialization and product launches. Thorsen has launched multiple oncology products that require infusion with buy and bill reimbursement, leveraging his skills in market analytics, commercial insights, go-to-market design and optimization, incentives, and training.